Evidence map›Paper›PMID 42655642›Full record

ArticleViruses2026

Orally Bioavailable SARS-CoV-2 Protease Inhibitors Bearing a Hydroxymethyl Ketone Warhead.

N G R Dayan Elshan, Karen C Wolff, Frank O Weiss, Sourav Ghorai, Gennadii Grabovyi, Katy Wilson, Laura Riva, Ashley K Woods, James R Pedroarena, Armen Nazarian and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

N G R Dayan ElshanCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-7830-1477
Karen C WolffCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Frank O WeissCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0009-0001-3100-7462
Sourav GhoraiCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Gennadii GrabovyiCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-8999-9532
Katy WilsonCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Laura RivaCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-2414-7341
Ashley K WoodsCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
James R PedroarenaCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Armen NazarianCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Yuyin LiuCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Wrickban MazumdarCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Lirui SongCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Neechi OkworCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0009-0002-8471-183X
Jacqueline MalvinCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Malina A BakowskiCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-3337-6528
Melanie G KirkpatrickCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0009-0008-4335-5342
Amal Gebara-LambCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0009-0003-2271-3116
Edward HuangCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0009-0000-8933-1321
Vân T B Nguyen-TranCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Stuart M WestonCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Carly DillenCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0001-5227-5952
Victor ChiCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Shuangwei LiCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Matthew B FriemanCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0003-0107-0775
Sumit K ChandaCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Kyoung-Jin LeeCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Case W McNamaraCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-5754-3407
Anil Kumar GuptaCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-5035-9597
Alireza RahimiCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Jian Jeffrey ChenCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-3847-8117
Sean B JosephCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Peter G SchultzCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.
Arnab K ChatterjeeCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037, USA.

Funding

Targeting druggable coronavirus proteinsU19AI171443 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Arnab Kumar Chatterjee · 2022 to 2026
$101.4M
Bill & Melinda Gates Foundation INV-028691Gates Foundation COVID-19 CTA GPP)Gates Foundation INV-028691NIAID NIH HHS U19 AI171443NIH HHS U19AI171443
6 · The paper itself

Abstract

The use of covalent warheads targeting the catalytic cysteine has been a cornerstone in the coronavirus main protease (M

Indexed as

Antiviral AgentsKetonesProtease InhibitorsSARS-CoV-2Administration, OralAnimalsBiological AvailabilityCoronavirus 3C ProteasesCOVID-19 Drug TreatmentHumansAntiviral AgentsCoronavirus 3C ProteasesKetonesProtease Inhibitors3CLproantiviralsHMKhydroxymethyl ketoneMproprotease inhibitorsSARS-CoV-2

Identifiers

PMID42655642
PMCPMC13517159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.